Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Hemophilia B Clinical Trials

21 recruiting trials for Hemophilia B. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
21
Total Trials
21
Recruiting Now
6
Phase 3 Trials
10
Sponsors

Recruiting Trials

RECRUITINGNCT06147414

Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders

Cell-free fetal DNA (cffDNA) is present in the maternal blood from the early first trimester of gestation and makes up 5%-20% of the total circulating cell-free DNA (cfDNA) in...

Sponsor: Assistance Publique - Hôpitaux de ParisEnrolling: 5501 location
RECRUITINGNCT06727669

Longitudinal Cohort of Thrombosis and Hemostasis Diseases

This is a multicenter, prospective, longitudinal, observational cohort study to investigate thrombosis and hemostasis diseases in Chinese patients. This study will collect basic...

Sponsor: Peking University People's HospitalEnrolling: 30005 locations
RECRUITINGPhase 1NCT05709288

Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old

This is a Phase 1, open- label, non- randomized, uncontrolled, single dose pilot study to evaluate the safety, tolerability and efficacy of a single intravenous infusion of...

Sponsor: Institute of Hematology & Blood Diseases Hospital, ChinaEnrolling: 91 location
RECRUITINGNCT06565481

Measurement Properties in People with Hemophilia

The aim of this project is to determine the measurement properties (namely reliability and validity) of a set of clinical assessments, measuring different aspects of physical...

Sponsor: University of ZurichEnrolling: 501 location
RECRUITINGPhase 3NCT06003387

Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment...

The purpose of this study is to assess the risk of bleeding due to failure of expected pharmacological action of CSL222 in adults with severe or moderately severe hemophilia B...

Sponsor: CSL BehringEnrolling: 3520 locations
RECRUITINGPhase 3NCT05145127

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

Study B7841007 is an open-label extension study to assess the long-term safety, tolerability, and efficacy of prophylaxis treatment with marstacimab in participants who did not...

Sponsor: PfizerEnrolling: 24520 locations
RECRUITINGPhase 3NCT05611801

A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called marstacimab) for the potential treatment of hemophilia in pediatric...

Sponsor: PfizerEnrolling: 10020 locations
RECRUITINGPhase 1 / Phase 2NCT05641610

A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients

A non-randomized, open-label, dose-escalation, phase I/II study to evaluate the safety, tolerability, kinetics and efficacy of a single intravenous infusion of ZS801 in hemophilia...

Sponsor: Institute of Hematology & Blood Diseases Hospital, ChinaEnrolling: 211 location
RECRUITINGPhase 3NCT07080905

Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or...

This is a phase 3, prospective, open-label, single-arm, single-dose, multicenter study investigating the efficacy, safety, and tolerability of CSL222 (AAV5-hFIXco-Padua) in...

Sponsor: CSL BehringEnrolling: 209 locations
RECRUITINGEarly Phase 1NCT05152732

Safety and Tolerability of VGB-R04 in Patients With Haemophilia B

An Open-Label, Non-Randomized, uncontrolled, single-dose pilot study of VGB-R04 in subjects with Hemophilia B.

Sponsor: Institute of Hematology & Blood Diseases Hospital, ChinaEnrolling: 31 location
RECRUITINGPhase 1 / Phase 2NCT06379789

A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265)...

Participants in this study have a genetic mutation, specifically in the coagulation (blood clotting) Factor 9 gene that causes severe or moderately severe hemophilia B. This study...

Sponsor: Regeneron PharmaceuticalsEnrolling: 13020 locations
RECRUITINGNCT06008938

An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B

This observational, post-authorization, long-term follow-up study aims to investigate the short and long-term effectiveness and safety of HEMGENIX in patients with hemophilia B....

Sponsor: CSL BehringEnrolling: 50012 locations
RECRUITINGNCT05630651

The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.

A non-randomized, open-label study to evaluate the safety, kinetics and efficacy of a single intravenous infusion of ZS801 in hemophilia B subjects with endogenous FIX ≤2%.

Sponsor: Institute of Hematology & Blood Diseases Hospital, ChinaEnrolling: 61 location
RECRUITINGNCT03327779

World Bleeding Disorders Registry

The WBDR is an international observational disease registry of patients with hemophilia. It will provide a platform for a network of hemophilia treatment centres (HTCs) around the...

Sponsor: World Federation of HemophiliaEnrolling: 200001 location
RECRUITINGPhase 1 / Phase 2NCT06611436

BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B

The BeCoMe-9 Study (BE-101-01) is a Phase 1/2, first in human, multi-center, open-label, dose-escalation study to evaluate the safety and clinical activity of a single intravenous...

Sponsor: Be BiopharmaEnrolling: 244 locations
RECRUITINGPhase 1NCT06349473

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A:...

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of SR604 in healthy participants (Part A) and to evaluate the...

Sponsor: Equilibra Bioscience LLCEnrolling: 3110 locations
RECRUITINGPhase 3NCT06700096

An Open-Label, Comparative Study of the Efficacy, Safety and Pharmacodynamics of Single Dose of ANB-002 in Patients...

The aim of the study is to demonstrate non-inferiority of ANB-002 compared with preventive use of coagulation factor IX (FIX) in adult subjects with hemophilia B with FIX activity...

Sponsor: BiocadEnrolling: 2414 locations
RECRUITINGPhase 1 / Phase 2NCT06120582

Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN)

The goal of this multicenter, two-stage, open-label study is to investigate the safety, immunogenicity, and efficacy of ANB-002 in subjects with hemophilia В. The study will have...

Sponsor: BiocadEnrolling: 2817 locations
RECRUITINGNCT04645199

National Longitudinal Cohort of Hematological Diseases

Background Hematological diseases are disorders of the blood and hematopoietic organs. The current hematological cohorts are mostly based on single-center or multi-center cases,...

Sponsor: Institute of Hematology & Blood Diseases Hospital, ChinaEnrolling: 23001 location
RECRUITINGNCT02912143

German Pediatric Hemophilia Research Database

The German Pediatric Hemophilia Research Database will collect data on the prophylactic and therapeutic use of factor concentrates, complications, outcome measures (joint scores,...

Sponsor: Goethe UniversityEnrolling: 8001 location
RECRUITINGPhase 3NCT05568719

Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B...

A study to learn about the long-term safety and efficacy of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B respectively, who...

Sponsor: PfizerEnrolling: 17316 locations